Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for WellPoint, Inc. (now Elevance Health) for the period ended June 30, 2006. WellPoint is the largest health benefits company in the U.S. by commercial membership, serving over 34 million members. The company operates through three segments: Health Care, Specialty, and Other. A significant event impacting this period was the acquisition of WellChoice, Inc., completed on December 28, 2005, which is fully consolidated in the 2006 results. The company also began marketing Medicare Part D Prescription Drug Plans effective January 1, 2006.
Key Financial Metrics (Six Months Ended June 30, 2006)
| Metric | 2006 (Unaudited) | 2005 (Unaudited) |
|---|---|---|
| Total Revenues | $27,971.6 million | $22,092.1 million |
| Net Income | $1,483.0 million | $1,171.1 million |
| Diluted EPS | $2.26 | $1.88 |
| Operating Cash Flow | $1,998.6 million | $1,591.3 million |
| Cash and Cash Equivalents | $1,934.4 million | $2,740.2 million (Dec 31, 2005) |
| Total Debt (Long-term + Current) | $7,468.8 million | $6,805.9 million (Dec 31, 2005) |
| Benefit Expense Ratio | 81.3% | 80.8% |
| SG&A Expense Ratio | 15.8% | 16.3% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27% year-over-year, driven primarily by the WellChoice acquisition, premium rate increases, and the launch of Medicare Part D. On a comparable basis (excluding acquisition impact), revenue grew 10%.
- Profitability: Net income increased 27% to $1.48 billion. Diluted EPS rose 20% to $2.26. The increase in net income was aided by the non-recurrence of a $103 million pre-tax expense related to a multi-district litigation (MDL) settlement recorded in 2005.
- Expense Trends: Benefit expense increased 27% to $20.7 billion. SG&A expenses increased 23% to $4.4 billion, partially due to the adoption of FAS 123R (share-based compensation) and volume-sensitive costs. However, the SG&A expense ratio improved by 50 basis points on a comparable basis.
- Investment Performance: Net investment income increased 44% to $430.6 million due to higher interest rates and acquired assets. However, the company recorded net realized losses on investments of $16.0 million, primarily due to sales of fixed maturity securities in a rising interest rate environment.
- Capital Allocation: The company repurchased approximately 48.0 million shares of common stock for $3.6 billion during the six-month period. Total authorized repurchases were increased to $4.0 billion.
Guidance, Outlook, and Risks
- Cost of Care: Management estimates the 2006 medical cost of care trend to be less than 8%. Outpatient trends are moderating, while inpatient trends are driven by unit costs. Pharmacy benefit cost trends remained unchanged.
- Medicare Part D: The company launched Medicare Part D plans in all 50 states in January 2006, enrolling approximately 1.5 million members by June 30. Management notes risks regarding underwriting assumptions and pharmaceutical costs for this new business.
- Accounting Changes: The adoption of FAS 123R effective January 1, 2006, resulted in a $141.1 million stock-based compensation expense for the six months ended June 30, 2006, reducing net income by approximately $56.9 million compared to the prior method.
- Legal Contingencies: The company is involved in various litigation, including the MDL settlement (approved in 2005 but subject to appeal) and disputes regarding reinsurance arrangements with John Hancock. Management believes these are unlikely to have a material adverse effect.
- Market Risks: The company is exposed to interest rate risk and equity market valuation risk. It utilizes interest rate swaps to hedge exposure on borrowings.
Investor Verification Checklist
- Medical Claims Reserves: Verify the adequacy of the $5.16 billion medical claims payable liability, noting the $556.7 million redundancy (favorable development) recognized in the current period.
- WellChoice Integration: Assess the realization of synergies and operating efficiencies from the WellChoice acquisition, as integration costs and disruption risks remain.
- Medicare Part D Performance: Monitor the profitability and enrollment growth of the new Medicare Part D business, which carries distinct underwriting risks.
- Stock Repurchase Program: Confirm the remaining authorization ($399.6 million as of June 30) and the company's commitment to returning capital to shareholders.
- Investment Portfolio: Review the impact of rising interest rates on the fair value of the $16.8 billion investment portfolio and potential for future other-than-temporary impairment charges.